跳至主要内容
临床试验/NCT04727775
NCT04727775已完成不适用

A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19

Astana Medical University2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2020年12月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
150
试验地点
2
主要终点
Outcome without comlications

研究概览

简要总结

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

详细描述

Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with COVID19 with medium and easy condition disease
  • take favipiravir/remdisivir control group
  • Patients with COVID19 with medium and easy condition disease
  • not take favipiravir/remdisivir

排除标准

  • patients younger 18
  • severe conditionis

研究组 & 干预措施

Complications

Evaluathion

干预措施: Favipiravir (Drug)

Complications

Evaluathion

干预措施: Remdesivir (Drug)

Oxygen status

Evaluathion

干预措施: Favipiravir (Drug)

Oxygen status

Evaluathion

干预措施: Remdesivir (Drug)

Oxugen support

Evaluathion

干预措施: Favipiravir (Drug)

Oxugen support

Evaluathion

干预措施: Remdesivir (Drug)

结局指标

主要结局

Outcome without comlications

时间窗: 14 days

The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2

次要结局

  • SpO2(14 days)
  • Respiratory rate(14 days)
  • Heart rate(14 days)
  • Blood pressure(14 days)

研究者

发起方
Astana Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Aidos Konkayev

doctor

Astana Medical University

研究点 (2)

Loading locations...

相似试验